Contagion&reg Editorial Staff

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Keith S. Kaye, MD, MPH, discusses the current treatment landscape for pneumonia in the ICU setting, and previews the topline results of the phase 3 RESTORE-IMI 2 trial.

Samuel L. Aitken, PharmD, MPH, discusses the article he wrote with Dr. Sarah L. Spitznogle for the October issue of Contagion® evaluating the role of new β-lactam agents for uncommon pathogens.

Anandi Sheth, MD, MSc, summarizes her presentation on HIV prevention in women and discusses the need for more women in pre-exposure prophylaxis research.

Jason Schafer, PharmD, MPH, BCPS AQ-ID, previews the October issue featuring an article on rapid initiation of antiretroviral therapy.

Pablo J. Sánchez, MD, discusses the need for NICU stewardship with Debra Goff, PharmD, and Pavel Prusakov, PharmD.

Helen Chu, MD, MPH, discussed the "Seattle Flu Study" with Contagion at IDWeek 2019.

Elizabeth Hirsch, PharmD, previews her piece with Mélanie Mahoney, PharmD student, on 2019 updates to CLSI breakpoints.

Hermione Hurley, MD, MCBhB, discusses the intersection of substance use disorder and infectious disease.

Jason Pogue, PharmD, BCPS, BCIDP, shares that SIDP will become the fifth partner in IDWeek, joining the Infectious Diseases Society of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society, and the Society for Healthcare Epidemiology of America.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of September 29, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of IDWeek 2019 to date.

Carlos del Rio, MD, co-director of Emory Center for AIDS Research, discusses the collaboration across specialties that is inherent in infectious disease.

The FDA has approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF).

Debra Goff, PharmD, discusses why it is critical to engage dentists and orthopedic surgeons in antimicrobial stewardship activities.

As September draws to a close, the Contagion® editorial team is recapping the trends and top infectious disease news of the month.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of September 22, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The Contagion® editorial staff will be providing exclusive written and video coverage from IDWeek 2019.

The FDA has approved treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to 8 weeks.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of September 15, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The approval allows treatment-experienced adults living with HIV who are virally suppressed to switch to doravirine or doravirine/lamivudine/tenofovir disoproxil fumarate.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of September 8, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

In this episode, we take a dual look at the recently announced changes to antibiotic reimbursements from the Centers for Medicare and Medicaid Services from both the clinician and industry perspective.